OPKO Health, Inc. (OPK): Lienzo del Modelo de Negocio [Actualizado en Ene-2025]

En el panorama dinámico de la innovación de la salud, Opko Health, Inc. (OPK) surge como una fuerza transformadora, navegando estratégicamente las complejas intersecciones de diagnósticos, productos farmacéuticos y medicina personalizada. Esta compañía de vanguardia ha creado meticulosamente un modelo de negocio que no solo impulsa el avance tecnológico, sino que también redefine cómo se desarrollan, entregan e integran las soluciones médicas en el ecosistema de atención médica global. Al aprovechar las asociaciones estratégicas, la investigación innovadora y un enfoque integral de la tecnología médica, Opko Health demuestra un compromiso extraordinario para revolucionar la atención del paciente y el diagnóstico médico.

OPKO Health, Inc. (OPK) - Modelo de negocios: asociaciones clave

Colaboración estratégica con compañías farmacéuticas

Opko Health ha establecido asociaciones estratégicas con las siguientes compañías farmacéuticas:

Empresa asociada	Enfoque de colaboración	Año establecido
Pfizer Inc.	Desarrollo de la hormona del crecimiento de Somatrogo	2019
Tesaro (adquirido por GSK)	Colaboración de tecnología de diagnóstico	2017

Asociaciones de investigación con instituciones académicas y médicas

OPKO Health mantiene colaboraciones de investigación con:

• Facultad de Medicina de la Universidad de Miami Miller
• Escuela de Medicina de Harvard
• Clínica de mayonesa

Acuerdos de distribución con proveedores de atención médica globales

Las asociaciones de distribución clave incluyen:

Proveedor de atención sanitaria	Cobertura geográfica	Enfoque del producto
Salud cardinal	Estados Unidos	Distribución de equipos de diagnóstico
McKesson Corporation	América del norte	Distribución farmacéutica

Acuerdos de licencia para tecnologías de diagnóstico

Opko Health ha asegurado acuerdos de licencia con:

• Laboratorios de biorreferencia
• GenEdx (tecnologías de prueba genética)

Empresas conjuntas en biotecnología e investigación médica

Inversiones de empresas conjuntas actuales:

Socio de empresa conjunta	Monto de la inversión	Área de investigación
Israel Chemicals Ltd.	$ 12.5 millones	Diagnóstico molecular
Diagnóstico de Ariosa	$ 35 millones	Prueba genética prenatal

OPKO Health, Inc. (OPK) - Modelo de negocio: actividades clave

Investigación y desarrollo farmacéutico

Gastos anuales de I + D en 2022: $ 162.1 millones

Áreas de enfoque de I + D	Asignación de inversión
Desarrollo biológico	42% del presupuesto de I + D
Tecnologías de diagnóstico	33% del presupuesto de I + D
Terapias de enfermedades raras	25% del presupuesto de I + D

Creación e innovación de las pruebas de diagnóstico

Portafolio de prueba de diagnóstico total: 17 pruebas de propiedad

• Plataforma de diagnóstico molecular 4D
• Tecnologías de prueba genética
• Soluciones de diagnóstico de medicina de precisión

Fabricación de productos biofarmacéuticos

Instalaciones de fabricación: 3 ubicaciones globales

Ubicación	Capacidad de fabricación
Miami, Florida	Producción de biológicos primarios
Israel	Fabricación farmacéutica especializada
Puerto Rico	Instalación de producción secundaria

Ensayos clínicos y pruebas médicas

Ensayos clínicos activos en 2022: 12 estudios en curso

• Ensayos de oncología: 4 estudios
• Endocrinología ensayos: 3 estudios
• Ensayos de enfermedades raras: 5 estudios

Comercialización de tecnologías de atención médica

Ingresos de tecnologías comercializadas en 2022: $ 1.47 mil millones

Segmento tecnológico	Ingresos comerciales
Soluciones de diagnóstico	$ 487 millones
Productos farmacéuticos	$ 683 millones
Terapéutica especializada	$ 300 millones

OPKO Health, Inc. (OPK) - Modelo de negocio: recursos clave

Tecnologías de diagnóstico y farmacéuticos patentados

Opko Health mantiene una cartera de 588 patentes a partir de 2023, con activos tecnológicos clave que incluyen:

• Prueba de diagnóstico de cáncer de próstata 4KScore
• Terapia hormonal de crecimiento de acción prolongada
• Rayaldee para enfermedad renal crónica

Investigaciones y instalaciones de desarrollo

Ubicación	Enfoque de investigación	Tamaño de la instalación
Miami, FL	Desarrollo farmacéutico	45,000 pies cuadrados.
San Diego, CA	Tecnologías de diagnóstico	32,000 pies cuadrados.

Cartera de propiedades intelectuales

Conteo total de patentes: 588 patentes

• Patentes de tecnología de diagnóstico: 276
• Patentes de tecnología farmacéutica: 312

Equipo experto en investigación científica y médica

Categoría de empleado	Número	Porcentaje
Investigar científicos	187	42%
Investigadores médicos	129	29%
Especialistas clínicos	130	29%

Equipo avanzado de laboratorio y prueba

Tipo de equipo	Cantidad	Valor total
Sistemas de cromatografía líquida de alto rendimiento (HPLC)	24	$ 3.6 millones
Espectrómetros de masas	18	$ 4.5 millones
Máquinas de secuenciación genética	12	$ 7.2 millones

OPKO Health, Inc. (OPK) - Modelo de negocio: propuestas de valor

Soluciones de diagnóstico innovadoras para la atención médica de precisión

El segmento de diagnóstico de Opko Health genera $ 295.2 millones en ingresos anuales (informe financiero de 2022). La División de Laboratorios Biorreference de la Compañía procesa aproximadamente 80 millones de pruebas de laboratorio anualmente.

Tecnología de diagnóstico	Volumen de prueba anual	Penetración del mercado
Prueba genética de precisión	1,2 millones de pruebas	Cuota de mercado del 14%
Diagnóstico molecular	3.5 millones de pruebas	Cuota de mercado del 9%

Tecnologías integrales de pruebas médicas

Opko Health invierte $ 127.6 millones anuales en I + D para tecnologías de pruebas médicas.

• Plataformas de detección molecular 4D
• Sistemas de análisis genómico avanzados
• Soluciones de flujo de trabajo de diagnóstico integrado

Tratamientos farmacéuticos avanzados

Ingresos del segmento farmacéutico: $ 412.7 millones (2022 año fiscal).

Producto farmacéutico	Venta anual	Segmento de mercado
Rayaldee (tratamiento de vitamina D)	$ 63.4 millones	Enfermedad renal crónica
Tratamientos inmunológicos argx	$ 89.6 millones	Trastornos autoinmunes

Diagnóstico de atención médica rentable

Reducción promedio de costos para pruebas de diagnóstico: 22% en comparación con los precios estándar de la industria.

• Plataformas de prueba automatizadas
• Capacidades de procesamiento a granel
• Infraestructura de laboratorio eficiente

Estrategias de detección e intervención médica personalizadas

Ingresos de detección personalizados: $ 176.3 millones (informe financiero de 2022).

Categoría de detección	Proyecciones anuales	Segmentos de pacientes
Evaluación de riesgos genéticos	245,000 pacientes	Oncología, condiciones hereditarias
Mapeo de intervención de precisión	167,000 pacientes	Manejo de enfermedades crónicas

OPKO Health, Inc. (OPK) - Modelo de negocios: relaciones con los clientes

Compromiso médico directo

OPKO Health mantiene la participación directa con los profesionales médicos a través de canales de comunicación específicos:

Método de compromiso	Volumen de interacción anual
Presentaciones de conferencia médica	37 conferencias científicas en 2023
Serie de seminarios web profesionales	24 seminarios médicos especializados
Contactos de representante de ventas directas	168 representantes de ventas dedicados

Soporte técnico para proveedores de atención médica

La infraestructura de soporte técnico para proveedores de atención médica incluye:

• Línea directa de soporte clínico 24/7
• Equipo de soporte técnico dedicado de 42 especialistas
• Base de conocimiento en línea con 1.287 documentos de recursos médicos

Plataformas de soporte de pacientes en línea

Característica de la plataforma	Métrica
Usuarios del portal de pacientes	87,643 usuarios registrados
Recursos de salud digital	463 documentos de información médica en línea
Descargas de aplicaciones móviles	56,291 descargas totales

Comunicación de investigación médica continua

Los canales de comunicación de investigación incluyen:

• Newsletters de actualización de investigación trimestral
• 12 Documentos de investigación clínica publicados en 2023
• Participación en 29 colaboraciones internacionales de investigación médica

Servicios de consulta de atención médica personalizada

Tipo de consulta	Volumen de servicio anual
Consultas de telesalud	14,672 consultas virtuales
Asesoramiento genético especializado	3.246 consultas personalizadas
Guía de medicina de precisión	2.893 consultas individuales

OPKO Health, Inc. (OPK) - Modelo de negocio: canales

Ventas directas a instituciones de atención médica

Opko Health emplea una fuerza de ventas directa dirigida a las instituciones de atención médica. A partir de 2023, la compañía mantuvo un equipo de ventas de aproximadamente 150 representantes especializados en líneas de productos farmacéuticos y de diagnóstico.

Tipo de canal de ventas	Número de representantes	Segmentos de atención médica objetivo
Ventas farmacéuticas	85	Hospitales, clínicas
Ventas de diagnóstico	65	Redes de laboratorio, instituciones de investigación

Plataformas médicas en línea

OPKO Health aprovecha las plataformas digitales para la distribución de productos y la difusión de información médica.

• Portal médico en línea con 45,000 profesionales de la salud registrados
• Catálogo de productos digitales con seguimiento de inventario en tiempo real
• Plataforma de integración de telemedicina

Conferencias y exposiciones médicas

Opko Health participa en aproximadamente 22 conferencias médicas internacionales anualmente, lo que representa una inversión de $ 1.2 millones en participación y marketing de conferencias.

Redes de distribuidores farmacéuticos

Tipo de distribuidor	Número de socios	Cobertura geográfica
Distribuidores farmacéuticos nacionales	12	Estados Unidos
Distribuidores internacionales	8	Europa, América Latina

Canales de marketing digital y comunicación médica

Presupuesto de marketing digital para 2023: $ 3.7 millones

• Participación en las redes sociales: 125,000 seguidores profesionales de atención médica
• Base de datos de marketing por correo electrónico: 87,000 contactos
• Serie de seminarios web que llegan a 15,000 profesionales médicos trimestralmente

OPKO Health, Inc. (OPK) - Modelo de negocio: segmentos de clientes

Proveedores de atención médica

Opko Health atiende a aproximadamente 12.500 proveedores de atención médica en los Estados Unidos a partir de 2023.

Tipo de proveedor	Número de clientes	Penetración del mercado
Médicos de atención primaria	6,800	54.4%
Especialistas	4,200	33.6%
Centros de atención urgente	1,500	12%

Hospitales y centros médicos

Opko Health atiende a 782 hospitales y centros médicos en todo el país en 2023.

• Centros médicos académicos: 124
• Hospitales comunitarios: 458
• Hospitales especializados: 200

Instituciones de investigación

OPKO Health colabora con 215 instituciones de investigación a nivel mundial.

Tipo de institución	Número de asociaciones
Centros de investigación universitarios	142
Institutos de Investigación Privada	73

Compañías farmacéuticas

Opko Health tiene asociaciones activas con 38 compañías farmacéuticas en 2023.

• Top 20 compañías farmacéuticas globales: 22
• Firmas farmacéuticas de tamaño mediano: 16

Pacientes individuales

OPKO Health atiende a aproximadamente 1,2 millones de pacientes individuales a través de servicios de diagnóstico y farmacéuticos.

Segmento de paciente	Número de pacientes
Prueba de diagnóstico	650,000
Tratamientos farmacéuticos	550,000

OPKO Health, Inc. (OPK) - Modelo de negocio: Estructura de costos

Extensos gastos de investigación y desarrollo

Opko Health, Inc. reportó gastos de I + D de $ 171.5 millones para el año fiscal 2022.

Año	Gastos de I + D	Porcentaje de ingresos
2022	$ 171.5 millones	33.2%
2021	$ 159.3 millones	31.8%

Inversiones de ensayos clínicos

Los costos de ensayos clínicos para Opko Health en 2022 fueron de aproximadamente $ 82.3 millones, centrándose en áreas terapéuticas clave.

• Ensayos clínicos biofarmacéuticos: $ 52.6 millones
• Investigación clínica de diagnóstico: $ 29.7 millones

Costos de fabricación y producción

Los gastos de fabricación totales para 2022 alcanzaron $ 214.6 millones.

Categoría de fabricación	Costo
Producción farmacéutica	$ 138.2 millones
Producción de equipos de diagnóstico	$ 76.4 millones

Gastos de marketing y ventas

Los gastos de marketing y ventas para Opko Health en 2022 totalizaron $ 97.4 millones.

• Marketing farmacéutico: $ 62.3 millones
• Marketing de diagnóstico: $ 35.1 millones

Gastos de cumplimiento y certificación regulatoria

Los costos de cumplimiento regulatorio para 2022 fueron de $ 24.7 millones.

Categoría de cumplimiento	Gastos
Cumplimiento de la FDA	$ 15.6 millones
Certificaciones regulatorias internacionales	$ 9.1 millones

OPKO Health, Inc. (OPK) - Modelo de negocios: flujos de ingresos

Ventas de pruebas de diagnóstico

En el año fiscal 2022, Opko Health generó $ 320.4 millones en ventas de pruebas de diagnóstico a través de su segmento de Laboratories Bioreference.

Categoría de prueba de diagnóstico	Ingresos (2022)
Prueba de Covid-19	$ 87.6 millones
Pruebas clínicas de rutina	$ 157.2 millones
Pruebas de diagnóstico especializadas	$ 75.6 millones

Ingresos de productos farmacéuticos

El segmento farmacéutico de Opko Health generó $ 184.9 millones en ingresos de productos en 2022.

• Rayaldee (tratamiento de vitamina D): $ 42.3 millones
• Varubi (medicación anti-nausea): $ 12.7 millones
• Otros productos farmacéuticos: $ 129.9 millones

Tasas de transferencia de licencias y tecnología

Opko Health reportó $ 23.5 millones en ingresos por licencias y transferencia de tecnología en 2022.

Socio de licencia	Área tecnológica	Monto de la tarifa
Pfizer	Somatrogo (hormona de crecimiento)	$ 15.2 millones
Otros socios farmacéuticos	Varias plataformas de biotecnología	$ 8.3 millones

Subvenciones y colaboraciones de investigación

Opko Health recibió $ 7.8 millones en subvenciones de investigación y financiación colaborativa en 2022.

Servicios de consulta de tecnología médica

Los servicios de consulta generaron $ 5.6 millones en ingresos adicionales para Opko Health en 2022.

Ingresos totales para 2022: $ 542.2 millones

OPKO Health, Inc. (OPK) - Canvas Business Model: Value Propositions

The value propositions for OPKO Health, Inc. (OPK) as of late 2025 center on specialized diagnostics and a focused, high-potential pharmaceutical pipeline, often structured through partnerships to mitigate risk.

Next-generation, long-acting human growth hormone therapy (NGENLA)

This value is delivered through a royalty arrangement with Pfizer Inc. (PFE), which handles ownership and distribution. The financial return is realized via gross profit sharing, which has shown variability:

• OPKO Health estimated annual gross profit share revenue for NGENLA between $28 million and $35 million for the full year 2025.
• Gross profit share payments totaled $6.1 million in the second quarter of 2025, down from $6.3 million in the second quarter of 2024.
• Gross profit share payments increased to $8.8 million in the third quarter of 2025, up from $7 million in the third quarter of 2024.
• The company earned $10.6 million from NGENLA profit share in the first six months of 2025.
• Analyst guidance for 2026 suggested a year-over-year flat expectation of $32-35 million.

Improved risk assessment for aggressive prostate cancer (4Kscore Test)

The value here is enhanced diagnostic accuracy, supported by regulatory milestones and market relevance:

• The U.S. Food and Drug Administration (FDA) approved a supplemental application in the second quarter of 2025, allowing the 4Kscore® Test to be performed without digital rectal examination (DRE) information.
• Clinical studies concluded the test is reliable with greater than 96% sensitivity and accuracy (n=937).
• The 4Kscore® Test franchise was part of the core clinical testing services that represented approximately $300 million in revenue for 2024.

Treatment for Secondary Hyperparathyroidism (SHPT) in chronic kidney disease patients (Rayaldee)

Rayaldee provides a treatment option for SHPT patients, with product sales showing modest movement in 2025:

Period	Rayaldee Net Sales (Millions USD)
Q1 2025	$6.3 million
Q2 2025	$7.2 million
Q3 2025	$7.5 million
Full Year 2023	$31.0 million

The third quarter of 2025 sales of $7.5 million represented a 29.3% increase from the prior-year period.

Streamlined, focused core clinical testing services in the New York/New Jersey region

Following the sale of oncology assets to Labcorp, the remaining diagnostics business is focused on core services, including the New York/New Jersey region operations:

• The core clinical testing services in the New York and New Jersey region represented approximately $300 million in revenue for 2024.
• Management provided an outlook that the remaining annual revenue from this focused business is approximately $300 million.
• Full-year 2025 guidance for total Revenue from Services was set between $400 million and $500 million, which includes $95 million to $105 million from the assets being sold.
• Third quarter 2025 Diagnostics revenue from services was $95.2 million.

Potential for novel oral treatments for obesity and metabolic disorders (OPK-88006 pipeline)

This represents a high-potential value stream via a partnership to develop a first-in-class oral therapy:

• OPK-88006 is a dual agonist of the GLP-1 and glucagon receptors, intended as a once-daily tablet.
• OPKO Health and Entera Bio expect to file an Investigational New Drug (IND) application later in 2025.
• OPKO Health will hold a 60% ownership interest and be responsible for 60% of the development costs in the collaboration.
• OPKO purchased approximately 3.7 million ordinary shares of Entera at $2.17 per share.

OPKO Health, Inc. (OPK) - Canvas Business Model: Customer Relationships

You're looking at how OPKO Health, Inc. manages its connections with the various groups it serves-from the doctors prescribing its drugs to the patients using its lab services. It's a mix of direct sales, high-level partnerships, and digital self-service.

Dedicated personal selling via field-based nephrology sales representatives for Rayaldee

For Rayaldee, the relationship is definitely hands-on, relying on field-based nephrology sales reps to drive adoption with specialists. This direct engagement is key for a specialty pharmaceutical product. We see the results of this effort reflected in the quarterly sales figures for the drug. For instance, Rayaldee sales hit $7.5 million in the third quarter of 2025, which was an increase from the $5.8 million seen in the third quarter of 2024. However, the first quarter of 2025 saw Rayaldee sales at $6.3 million, a slight dip from the $6.9 million in the first quarter of 2024, and Q2 2025 sales were flat year-over-year at $7.2 million. This fluctuation shows the ongoing effort required in this relationship channel.

Co-development and licensing management with large pharmaceutical partners

Managing relationships with big pharma partners is crucial, especially for monetizing the pipeline through licensing. Take NGENLA, for example, which is on a royalty arrangement with Pfizer Inc. Management estimated full-year 2025 royalty revenue from this to be between $28 million and $35 million, a potential step up from the prior year's profit-share revenue of $28.3 million. The second quarter of 2025 saw royalty payments of $6.1 million. Then there's the ModeX collaboration with Regeneron Pharmaceuticals. This relationship is structured for massive upside, with OPKO Health, Inc. entitled to an upfront payment and potential milestone payments exceeding $200 million for each program, pushing the overall collaboration value potentially past $1 billion if multiple products succeed. Regeneron handles all the development and commercialization costs, which is a very strong customer/partner dynamic for OPKO Health, Inc.

Self-service digital Patient Portal for lab results and billing (BioReference)

For the diagnostics side, which is now more focused after the Labcorp asset sale, the relationship is heavily digitized through the BioReference Patient Portal. This is a self-service channel where patients can access their most recent laboratory reports, review past results, pay their bill, and update insurance information all online. Following the sale of the oncology and related clinical testing assets, the remaining BioReference core clinical testing services, including the 4Kscore Test franchise, continue to rely on this portal for patient interaction. While specific user numbers aren't public, the portal's existence supports a high-volume service model.

Shared decision-making support tools for physicians and patients (4Kscore Test)

The 4Kscore Test is a prime example of a tool designed to foster shared decision-making. This blood test, which combines four biomarkers with clinical factors, provides a numerical value to assess the risk of aggressive prostate cancer before a biopsy. The 4Kscore Test franchise itself represented approximately $300 million in revenue for BioReference in 2024. Historically, the test has been utilized by over 7,700 health care providers, including about 4,200 urologists, as of a 2021 report. OPKO Health, Inc. confirmed that BioReference will continue to offer this comprehensive Urology diagnostic service nationwide, meaning this decision-support relationship remains a core offering.

Customer Service teams available 24/7 for healthcare provider inquiries

For healthcare providers needing support with BioReference services, there are dedicated contact channels. While the outline specifies 24/7 availability, the publicly available contact information lists specific phone numbers for billing inquiries (e.g., 833-469-5227) and patient portal support (e.g., 1-888-279-0967, M-F 9AM-5PM ET for login issues), alongside general corporate contact numbers. The existence of these dedicated lines shows a commitment to addressing provider needs, which is vital for maintaining lab service relationships.

Here's a quick look at some of the key financial and statistical touchpoints related to these customer and partner relationships as of late 2025:

Relationship/Product Metric	Latest Reported Value (2025)	Context/Period
Rayaldee Product Revenue	$7.5 million	Q3 2025
Rayaldee Product Revenue	$6.3 million	Q1 2025
NGENLA Royalty Revenue Estimate (Low End)	$28 million	Full Year 2025 Guidance
NGENLA Royalty Payment Received	$6.1 million	Q2 2025
ModeX/Regeneron Potential Milestone Payments (Per Program)	Exceeding $200 million	Per Program
4Kscore Test Franchise Revenue	Approx. $300 million	2024 Annualized Figure
BioReference Headcount (Pre-Transaction Target)	1,450-1,500	Expected by Q4 post-transaction

Finance: draft 13-week cash view by Friday.

OPKO Health, Inc. (OPK) - Canvas Business Model: Channels

You're looking at how OPKO Health, Inc. gets its products and services into the hands of patients and providers as of late 2025. It's a mix of relying on big pharma muscle, a focused internal team, and established lab infrastructure.

Global Distribution Network Managed by Partners

For NGENLA, the growth hormone therapy, distribution is handled entirely by the partner, Pfizer. This channel provides global reach, with NGENLA now approved in over 40 markets worldwide. This partnership structure directly translates into royalty/profit share revenue for OPKO Health, Inc. For the third quarter of 2025, the gross profit share payments for NGENLA hit $8.8 million. Looking ahead, the guidance for NGENLA sales in 2026 is set between $32 million and $35 million.

Direct Sales Force Targeting Specialists in the U.S.

For its own pharmaceutical product, Rayaldee, OPKO Health, Inc. relies on a dedicated, specialized sales force within the U.S. targeting nephrologists. While the specific 2025 headcount isn't public, the company previously had plans to expand its field-based nephrology sales representatives to 70. This team supports the commercialization efforts for Rayaldee, which generated $7.5 million in revenue in the third quarter of 2025.

• NGENLA distribution is managed by Pfizer globally.
• Rayaldee commercialization is supported by a specialized U.S. sales team.
• Rayaldee is marketed in the U.S., Germany, Switzerland and Denmark.

BioReference Patient Service Centers and Mobile Phlebotomy Services

The diagnostics arm, primarily through BioReference Laboratories, utilizes a massive physical footprint for sample collection. BioReference Laboratories services approximately 11 million patients annually. Even after the sale of certain oncology assets, the core clinical testing operations in New York and New Jersey, which include some patient service centers (PSCs), represented approximately $300 million in revenue for 2024. The mobile component is supported by a logistics fleet of over 475 cars, driving over 17 million miles annually to support sample collection and delivery.

Specialty Pharmacies and Pharmaceutical Wholesalers for Rayaldee Distribution

Rayaldee, the treatment for secondary hyperparathyroidism, moves through traditional pharmaceutical supply channels. Shipments commence to distributors, making the product available nationwide at retail pharmacies. This channel is critical for reaching the adult patients with stage 3 or 4 chronic kidney disease and vitamin D insufficiency who are not on dialysis.

Provider Login Portals for Secure, 24/7 Access to Test Data and EHR Integration

For its diagnostic services, OPKO Health, Inc. provides digital access points for ordering and results retrieval. The company maintains a Provider Login portal, which is the mechanism for healthcare professionals to get secure, 24/7 access to test data. This digital channel is key for integrating results into the provider workflow, especially for tests like the 4Kscore® Test, which is reliable with over 96% sensitivity and accuracy in assessing aggressive prostate cancer probability.

Here's a quick look at the revenue and scale associated with these channels as of late 2025 data:

Channel/Product Metric	Latest Reported Value/Amount	Period/Context
NGENLA Gross Profit Share Revenue	$8.8 million	Q3 2025
NGENLA Global Approvals	Over 40 markets	Late 2025
Rayaldee Revenue	$7.5 million	Q3 2025
BioReference Annual Patient Volume	Approximately 11 million	Latest Data
BioReference NY/NJ Core Revenue	Approximately $300 million	2024
4Kscore Test Accuracy	Over 96%	Latest Data

Finance: review Q4 2025 revenue projections based on NGENLA profit share run rate by next Tuesday.

OPKO Health, Inc. (OPK) - Canvas Business Model: Customer Segments

Global pharmaceutical companies seeking co-development and licensing deals

• ModeX collaboration potential value exceeds $1 billion upon success of multiple products.
• ModeX eligible for tiered royalties on global net sales, up to low double digits at the highest tier.
• Ongoing Phase 1 clinical trial for Epstein-Barr virus vaccine with Merck.
• Collaboration with Entera Bio for oral tablet development.

Patients with pediatric growth hormone deficiency (NGENLA)

Metric	Q3 2025 Amount	Q2 2025 Amount	Q1 2025 Amount	2024 Amount
Gross Profit Share Revenue (USD)	$8.8 million	$6.1 million	$4.5 million	$28.3 million (Profit-share revenue)
Estimated Full Year 2025 Profit Share (USD)	$28 million to $35 million (Estimate)
2026 Guidance Range (USD)	$32 million to $35 million (Guidance)

Adult patients with Stage 3 or 4 Chronic Kidney Disease and SHPT (Rayaldee)

Metric	Q3 2025 Revenue (USD)	Q2 2025 Revenue (USD)	Q1 2025 Revenue (USD)
Rayaldee Sales	$7.5 million	$7.2 million	$6.3 million

Urologists and Primary Care Physicians utilizing the 4Kscore Test

• The 4Kscore Test franchise represented approximately $300 million in revenue for 2024.
• Test volume increased year-over-year by approximately 12% in Q2 2025.
• Over 90% of PSA screening tests are performed by primary care providers, potential users.
• FDA approved supplemental application in July 2025 enabling performance without digital rectal examination (DRE) information.

Healthcare providers and patients in the New York/New Jersey region for core clinical testing

Metric	Q3 2025 Revenue (USD)	Q2 2025 Revenue (USD)	Q1 2025 Revenue (USD)
Diagnostics Segment Revenue from Services	$95.2 million	$101.1 million	$102.8 million
Estimated Annualized Revenue (Remaining Business)	Approximately $300 million annually

The remaining BioReference business is expected to reach profitability this year. Finance: draft 13-week cash view by Friday.

OPKO Health, Inc. (OPK) - Canvas Business Model: Cost Structure

You're looking at the expense side of OPKO Health, Inc.'s operations as of late 2025, which is heavily influenced by its dual focus on pharmaceuticals in development and a streamlined diagnostics business. Here's a breakdown of the major cost drivers based on the third quarter of 2025 results.

The company's operating expenses reflect significant investment in its pipeline alongside cost management in its lab services arm. Research and development (R&D) expenses, totaling $30.1 million in Q3 2025, represent a key outlay for future growth potential. This figure is up 4.5% year over year, driven largely by activities within the ModeX development programs.

Selling, General, and Administrative (SG&A) expenses were reported at $53.8 million for the third quarter of 2025, showing a substantial decline of 45.2% compared to the prior-year quarter, which reflects the impact of strategic realignment and asset sales.

The overall cost structure is detailed in the table below, incorporating the reported revenue and profit figures to derive the cost of revenue components for both segments.

Cost Category	Q3 2025 Amount (Millions USD)	Notes
Research and Development (R&D) Expenses	$30.1	Primarily for pharmaceutical pipeline advancement, including ModeX programs.
Selling, General, and Administrative (SG&A) Expenses	$53.8	Declined 45.2% year over year due to cost containment.
Cost of Revenue (Calculated)	Approx. $101.8	Calculated as Total Revenue ($151.7M) less Gross Profit ($49.9M).
Nonrecurring Costs (Severance)	Approx. $4.2	Expected nonrecurring costs for severance during Q3 2025.

Cost of revenue is a major component, reflecting the operational expenses tied directly to generating the $95.2 million in diagnostic services revenue and $37.7 million in pharmaceutical product revenue for the quarter. The decrease in diagnostics cost of revenue is directly linked to the sale of certain BioReference assets, which saw cost and expenses drop significantly compared to the prior year.

Clinical trial costs are embedded within the R&D spend, specifically supporting pipeline candidates. You see activity across several fronts:

• The Merck and ModeX collaboration on the Epstein-Barr virus vaccine candidate, which entered Phase 1 study in early 2025.
• Advancement of ModeX tetraspecific antibody candidates, with some expected to enter human trials in late 2025 or early 2026.
• Development costs for the oral GLP-1/glucagon tablet candidate with Entera Bio, where OPKO Health is responsible for 60% of development costs.

Restructuring efforts have yielded significant expense reductions, particularly within the Diagnostics business following the Labcorp transaction. While the sale itself generated gains, the underlying cost structure was targeted for efficiency. Management has noted that cost-reduction initiatives were in place, with annualized savings of over $25 million expected from prior restructuring efforts. Furthermore, the company recorded approximately $4.2 million in expected nonrecurring severance costs in Q3 2025 alone.

Finance: draft 13-week cash view by Friday.

OPKO Health, Inc. (OPK) - Canvas Business Model: Revenue Streams

You're looking at how OPKO Health, Inc. (OPK) brings in cash as of late 2025. The revenue picture is clearly segmented across its Diagnostics and Pharmaceuticals divisions, with a notable contribution from non-core activities like IP monetization. This mix shows a company balancing service-based lab revenue with product sales and strategic financial events.

Here is a look at the key revenue components from the third quarter of 2025, which gives you a snapshot of the current operational flow:

Revenue Source	Q3 2025 Amount
Revenue from services (Diagnostics)	$95.2 million
Revenue from product sales (Pharmaceuticals)	$37.7 million
Revenue from the transfer of intellectual property and other	$18.8 million
Gross profit share payments from partners for NGENLA	$8.8 million

The Diagnostics segment, driven by BioReference Health, remains the largest top-line contributor, though it has been streamlined following asset sales. The Pharmaceutical revenue stream is more diverse than just product sales, so you need to watch the non-product elements closely. These are the specific revenue drivers you should be tracking:

• Revenue from services (Diagnostics), which was $95.2 million in Q3 2025.
• Revenue from product sales (Pharmaceuticals), totaling $37.7 million in Q3 2025.
• Revenue from the transfer of intellectual property and other, which was $18.8 million in Q3 2025.
• Gross profit share payments from partners for NGENLA, totaling $8.8 million in Q3 2025.

To be fair, the IP and other category is where you see the impact of deals like the one with Regeneron, plus royalties. Looking ahead, the full-year 2025 total revenue guidance is projected to be between $640 million and $660 million, which suggests the fourth quarter needs to perform solidly to hit that range after the Q3 results. Finance: draft 13-week cash view by Friday.